Kennedy Capital Management LLC grew its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 13.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,606 shares of the medical instruments supplier's stock after acquiring an additional 8,700 shares during the period. Kennedy Capital Management LLC owned about 1.37% of Mesa Laboratories worth $9,838,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at $32,677,000. Resona Asset Management Co. Ltd. purchased a new stake in shares of Mesa Laboratories during the 4th quarter worth about $92,000. ExodusPoint Capital Management LP grew its position in shares of Mesa Laboratories by 283.8% during the 4th quarter. ExodusPoint Capital Management LP now owns 9,692 shares of the medical instruments supplier's stock valued at $1,278,000 after acquiring an additional 7,167 shares during the period. Alliancebernstein L.P. increased its stake in shares of Mesa Laboratories by 2.6% in the 4th quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock valued at $736,000 after purchasing an additional 141 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Mesa Laboratories in the 4th quarter worth about $1,888,000. Institutional investors and hedge funds own 90.60% of the company's stock.
Mesa Laboratories Price Performance
MLAB traded up $1.43 during trading on Tuesday, hitting $115.52. The company's stock had a trading volume of 45,405 shares, compared to its average volume of 38,838. The firm has a market capitalization of $627.74 million, a price-to-earnings ratio of -2.50 and a beta of 0.92. Mesa Laboratories, Inc. has a twelve month low of $83.68 and a twelve month high of $155.12. The business's fifty day simple moving average is $129.73 and its 200 day simple moving average is $128.11. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 EPS for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.
Mesa Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.64 annualized dividend and a yield of 0.55%. Mesa Laboratories's dividend payout ratio (DPR) is -1.38%.
Insider Transactions at Mesa Laboratories
In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the sale, the chief executive officer now directly owns 43,337 shares in the company, valued at $5,369,887.67. This represents a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.40% of the company's stock.
Mesa Laboratories Company Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
See Also
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
